To tack­le su­per­bug scourge and re­vive R&D, in­cen­tivize FDA an­tibi­ot­ic ap­provals — drug­mak­ers, health groups urge US law­mak­ers

As su­per­bugs flour­ish, the in­dus­try play­ers con­tribut­ing to the ar­se­nal of an­timi­cro­bials are dwin­dling. Drug­mak­ers are en­ticed by green­er pas­tures, com­pared to the long ar­du­ous …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER